Advaxis (NASDAQ:ADXS) was downgraded by research analysts at Jefferies Financial Group from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday, The Fly reports.
Several other brokerages have also recently commented on ADXS. Cantor Fitzgerald dropped their target price on Advaxis from $19.00 to $5.00 and set an “overweight” rating on the stock in a report on Tuesday, March 13th. HC Wainwright set a $6.00 target price on Advaxis and gave the stock a “buy” rating in a report on Wednesday, March 14th. Finally, ValuEngine raised Advaxis from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd. Two investment analysts have rated the stock with a hold rating and three have given a buy rating to the stock. Advaxis currently has an average rating of “Buy” and a consensus price target of $4.00.
ADXS opened at $1.84 on Wednesday. The company has a market cap of $97.35 million, a PE ratio of -0.80 and a beta of 1.40. Advaxis has a twelve month low of $1.51 and a twelve month high of $7.84.
Advaxis (NASDAQ:ADXS) last announced its earnings results on Monday, March 12th. The biotechnology company reported ($0.49) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.55) by $0.06. Advaxis had a negative return on equity of 168.35% and a negative net margin of 1,041.73%. The firm had revenue of $2.06 million for the quarter, compared to analysts’ expectations of $3.03 million. sell-side analysts forecast that Advaxis will post -1.73 EPS for the current year.
A number of large investors have recently made changes to their positions in ADXS. BlackRock Inc. raised its holdings in Advaxis by 28.2% during the first quarter. BlackRock Inc. now owns 2,925,417 shares of the biotechnology company’s stock worth $4,943,000 after purchasing an additional 644,201 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Advaxis during the fourth quarter worth approximately $1,398,000. DAFNA Capital Management LLC raised its holdings in Advaxis by 182.2% during the first quarter. DAFNA Capital Management LLC now owns 697,000 shares of the biotechnology company’s stock worth $1,178,000 after purchasing an additional 450,000 shares in the last quarter. Deutsche Bank AG raised its holdings in Advaxis by 1,200.1% during the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock worth $1,326,000 after purchasing an additional 431,379 shares in the last quarter. Finally, Bank of Montreal Can raised its holdings in Advaxis by 16,465.9% during the fourth quarter. Bank of Montreal Can now owns 433,198 shares of the biotechnology company’s stock worth $1,230,000 after purchasing an additional 430,583 shares in the last quarter. 32.94% of the stock is currently owned by hedge funds and other institutional investors.
Advaxis Company Profile
Advaxis, Inc, a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based immunotherapies in the United States. It is developing Axalimogene filolisbac and ADXS-Dual that are Lm-LLO immunotherapy product candidates for the treatment of human papilloma virus associated cancers, including cervical, and head and neck cancers.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.